Monthly Cost Breakdown: Wegovy vs Mounjaro Pricing
Understanding Wegovy and Mounjaro Dose Comparison for Monthly Budgeting
When evaluating Wegovy and Mounjaro dose comparison for ongoing treatment, monthly cost planning becomes essential for sustainable weight management. Wegovy follows a structured 16-week escalation from 0.25mg to 2.4mg maintenance, whilst Mounjaro uses a 12-week progression from 2.5mg to maintenance doses of 5mg, 10mg, or 15mg depending on individual response. The different escalation timelines mean your monthly costs will vary during the initial months before reaching your maintenance dose. Understanding these patterns helps you budget effectively for long-term treatment success.
The Wegovy and Mounjaro dose comparison reveals distinct approaches to GLP-1 receptor activation, with Wegovy containing semaglutide (single GLP-1 agonist) and Mounjaro containing tirzepatide (dual GIP/GLP-1 agonist). These pharmacological differences influence both dosing schedules and associated monthly costs. Wegovy's longer escalation period spreads the dose increases over 16 weeks, providing a gentler financial progression compared to Mounjaro's more rapid 12-week escalation. Both medications require clinical assessment and ongoing prescriber supervision throughout treatment.
Wegovy Monthly Cost Breakdown: Complete Dose Escalation Pricing
The Wegovy dose escalation creates a predictable monthly cost structure starting at £79.99 for the 0.25mg starter dose with FIRST40 discount code. Month two increases to £94.99 for 0.5mg, followed by £99.99 for 1mg in month three, then £139.99 for 1.7mg in month four. From month five onwards, the maintenance 2.4mg dose costs £209.99 monthly. Returning customers benefit from the DOSE25 code, ensuring consistent savings throughout their treatment journey. This transparent pricing structure allows for accurate long-term budgeting without hidden costs or unexpected price increases.
Our bundle options provide additional convenience for Wegovy treatment, with the Intro Duo (0.25mg & 0.5mg) available for £169.99, covering your first two months. The Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 provides three months of mid-escalation supply, whilst the Ultimate Stability Trio offers three months of maintenance 2.4mg doses for £649.99. These bundles reduce ordering frequency and ensure treatment continuity, particularly valuable for the maintenance phase where consistent supply becomes crucial for ongoing weight management success.
Clinical Evidence Supporting Wegovy and Mounjaro Dose Comparison Decisions
In clinical trials, patients taking Wegovy alongside diet and exercise achieved an average of approximately clinically studied weight loss at 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021). The STEP trial programme demonstrated that the 2.4mg maintenance dose provided optimal efficacy whilst maintaining tolerability for most patients. Mounjaro's clinical programme showed varying results across different maintenance doses, with higher doses generally associated with greater weight reduction but requiring individual tolerance assessment.
The SELECT cardiovascular outcomes trial demonstrated that Wegovy may reduce major cardiovascular events by 20% compared to placebo in adults with established cardiovascular disease. This additional clinical benefit consideration extends beyond weight management alone, potentially influencing the long-term value proposition despite monthly medication costs. Both medications require prescription-only access and ongoing clinical monitoring to ensure appropriate use and dosing adjustments.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of natural incretin hormones in your digestive system. When you inject Wegovy once weekly, it activates GLP-1 receptors in your brain's appetite control centres, potentially reducing hunger signals and promoting feelings of fullness after smaller meals. The medication may also slow gastric emptying, helping you feel satisfied for longer periods after eating. This mechanism works alongside your reduced-calorie diet and increased physical activity to support sustainable weight management. The once-weekly injection schedule using the FlexTouch pen device provides consistent medication levels throughout the week, supporting steady appetite regulation. Understanding this mechanism helps explain why the gradual dose escalation is necessary to allow your body to adjust whilst maximising therapeutic benefits.
Streamlined Ordering Process: From Assessment to Delivery
EverydayMeds provides a comprehensive prescription service starting with a 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our qualified prescribers review your assessment within 3 working days (or 24 hours with express service), ensuring Wegovy is clinically appropriate for your individual circumstances. Once approved, your medication ships via next-day delivery using temperature-controlled cold-chain transport to maintain product integrity. The process includes clear dosing instructions, injection technique guidance, and ongoing support throughout your treatment. Our GPhC-registered pharmacy (#9012878) ensures all regulatory requirements are met whilst providing convenient access to this prescription-only medicine. Regular follow-up assessments ensure continued treatment appropriateness and dose optimisation.
Storage and Practical Considerations for Wegovy vs Mounjaro
Wegovy requires refrigerated storage at 2-8°C before first use but offers superior travel convenience with 6 weeks of room temperature stability below 30°C once removed from the fridge. This compares favourably to Mounjaro's 21-day room temperature limit, providing greater flexibility for holidays, business travel, or temporary storage situations. The Wegovy FlexTouch pen delivers precise doses through a simple click-counting mechanism, whilst both medications require weekly injection rotation between different body sites. The 16-week Wegovy escalation schedule requires careful dose progression without skipping steps, ensuring optimal tolerance and therapeutic response. Proper storage maintains medication effectiveness throughout the treatment period, protecting your investment in long-term weight management. Both medications should never be frozen or exposed to direct sunlight, with used pens requiring safe disposal through pharmacy take-back programmes.
Long-term Financial Planning: Annual Wegovy and Mounjaro Dose Comparison Costs
Annual cost planning for Wegovy treatment totals approximately £2,879.95 including the four-month escalation period plus eight months at maintenance dose (£209.99 monthly). This compares to Mounjaro's variable annual costs depending on your final maintenance dose selection and individual prescriber recommendations. The Wegovy cost structure provides predictable budgeting once you reach maintenance dosing, with consistent £209.99 monthly expenses and ongoing DOSE25 discount eligibility. Understanding these annual commitments helps evaluate the long-term investment in prescription weight management therapy.
Both medications represent significant financial commitments requiring careful consideration alongside potential health benefits and quality of life improvements. The structured Wegovy pricing eliminates guesswork about ongoing costs, whilst insurance coverage varies significantly between providers and individual policies. Some patients find the predictable Wegovy cost structure easier to manage financially compared to Mounjaro's variable maintenance dosing options. EverydayMeds' transparent pricing ensures no hidden fees or unexpected charges throughout your treatment journey.
Making Your Decision: Wegovy and Mounjaro Dose Comparison Summary
The Wegovy and Mounjaro dose comparison ultimately depends on individual clinical factors, tolerance patterns, and financial considerations that your prescriber will evaluate. Wegovy's single-agent semaglutide mechanism and established cost structure from £79.99 monthly provides a well-documented treatment pathway with predictable expenses. Mounjaro's dual-agonist tirzepatide mechanism offers an alternative approach with different dosing flexibility but requires individual cost assessment based on maintenance dose requirements. Both medications are available from EverydayMeds with comprehensive prescriber support to help determine which option suits your specific circumstances. The choice between these prescription-only medicines should prioritise clinical appropriateness alongside practical considerations including monthly costs, storage requirements, and long-term treatment sustainability. Our clinical team provides ongoing guidance throughout your weight management journey, ensuring optimal treatment outcomes whilst managing financial commitments effectively.
Ready to start your weight management journey? Complete our 3-minute clinical assessment and discover whether Wegovy is right for you. New customers save with code FIRST40, whilst returning customers continue saving with DOSE25 at checkout. Visit https://everydaymeds.co.uk/collections/wegovy to begin your consultation today. Our qualified prescribers provide expert guidance on dosing, costs, and treatment expectations throughout your journey. With transparent pricing, convenient delivery, and ongoing clinical support, EverydayMeds makes prescription weight management accessible and affordable. Take the first step towards sustainable weight management with confidence in our GPhC-registered service (#9012878).
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
